首页> 美国卫生研究院文献>PLoS Biology >Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
【2h】

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

机译:mTOR的活性部位抑制剂靶向抗雷帕霉素的mTORC1和mTORC2输出

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The mammalian target of rapamycin (mTOR) regulates cell growth and survival by integrating nutrient and hormonal signals. These signaling functions are distributed between at least two distinct mTOR protein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to the selective inhibitor rapamycin and activated by growth factor stimulation via the canonical phosphoinositide 3-kinase (PI3K)→Akt→mTOR pathway. Activated mTORC1 kinase up-regulates protein synthesis by phosphorylating key regulators of mRNA translation. By contrast, mTORC2 is resistant to rapamycin. Genetic studies have suggested that mTORC2 may phosphorylate Akt at S473, one of two phosphorylation sites required for Akt activation; this has been controversial, in part because RNA interference and gene knockouts produce distinct Akt phospho-isoforms. The central role of mTOR in controlling key cellular growth and survival pathways has sparked interest in discovering mTOR inhibitors that bind to the ATP site and therefore target both mTORC2 and mTORC1. We investigated mTOR signaling in cells and animals with two novel and specific mTOR kinase domain inhibitors (TORKinibs). Unlike rapamycin, these TORKinibs (PP242 and PP30) inhibit mTORC2, and we use them to show that pharmacological inhibition of mTOR blocks the phosphorylation of Akt at S473 and prevents its full activation. Furthermore, we show that TORKinibs inhibit proliferation of primary cells more completely than rapamycin. Surprisingly, we find that mTORC2 is not the basis for this enhanced activity, and we show that the TORKinib PP242 is a more effective mTORC1 inhibitor than rapamycin. Importantly, at the molecular level, PP242 inhibits cap-dependent translation under conditions in which rapamycin has no effect. Our findings identify new functional features of mTORC1 that are resistant to rapamycin but are effectively targeted by TORKinibs. These potent new pharmacological agents complement rapamycin in the study of mTOR and its role in normal physiology and human disease.
机译:雷帕霉素(mTOR)的哺乳动物靶标通过整合营养素和激素信号来调节细胞的生长和存活。这些信号传导功能分布在至少两种不同的mTOR蛋白复合物之间:mTORC1和mTORC2。 mTORC1对选择性抑制剂雷帕霉素敏感,并通过典型的磷酸肌醇3激酶(PI3K)→Akt→mTOR途径受生长因子刺激而被激活。激活的mTORC1激酶通过使mRNA翻译的关键调节子磷酸化来上调蛋白质合成。相反,mTORC2对雷帕霉素具有抗性。遗传研究表明,mTORC2可能在S473处磷酸化Akt,这是Akt激活所需的两个磷酸化位点之一。这一直是有争议的,部分原因是RNA干扰和基因敲除产生了独特的Akt磷酸同工型。 mTOR在控制关键细胞生长和存活途径中的核心作用激发了人们对发现与ATP位点结合并因此靶向mTORC2和mTORC1的mTOR抑制剂的兴趣。我们研究了两种新型和特异性的mTOR激酶域抑制剂(TORKinibs)在细胞和动物中的mTOR信号传导。与雷帕霉素不同,这些TORKinib(PP242和PP30)抑制mTORC2,我们用它们来证明对mTOR的药理抑制作用可阻断S473处Akt的磷酸化并阻止其完全活化。此外,我们显示TORKinibs比雷帕霉素更完全地抑制原代细胞的增殖。出乎意料的是,我们发现mTORC2不是这种增强活性的基础,并且我们证明TORKinib PP242比雷帕霉素更有效的mTORC1抑制剂。重要的是,在分子水平上,PP242在雷帕霉素无效的条件下抑制帽依赖性翻译。我们的发现确定了mTORC1的新功能特征,这些特征对雷帕霉素具有抗性,但可被TORKinib有效靶向。这些强大的新药理学药物在雷帕霉素的研究及其在正常生理学和人类疾病中的作用方面是雷帕霉素的补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号